Comparative Pharmacology
Head-to-head clinical analysis: VITRASERT versus ZOVIRAX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: VITRASERT versus ZOVIRAX.
VITRASERT vs ZOVIRAX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Vitrasert (ganciclovir implant) releases ganciclovir, a nucleoside analog that inhibits cytomegalovirus (CMV) replication by competitively inhibiting viral DNA polymerase (UL54) after intracellular phosphorylation to ganciclovir triphosphate. This results in chain termination and viral DNA synthesis inhibition.
After intracellular phosphorylation to acyclovir triphosphate, selectively inhibits viral DNA polymerase and incorporates into viral DNA, causing chain termination.
Intravitreal implant containing 0.59 mg fluocinolone acetonide; inserted into the vitreous cavity; releases drug over approximately 36 months; no systemic dosing.
Herpes simplex: 200 mg orally 5 times daily for 10 days; or 400 mg orally 3 times daily for 5-10 days. Herpes zoster: 800 mg orally 5 times daily for 7-10 days. IV: 5-10 mg/kg every 8 hours for immunocompromised patients with HSV/VZV.
None Documented
None Documented
Terminal half-life of 2.8 hours following intravitreal injection; sustained local levels for 2-3 weeks.
Terminal elimination half-life is 2.5-3.3 hours in adults with normal renal function; prolonged to 19.5 hours in anuria (creatinine clearance <10 mL/min).
Primarily biliary/fecal (approximately 90%) with minimal renal excretion (<10% unchanged in urine).
Renal excretion of unchanged drug via glomerular filtration and tubular secretion accounts for 76-82% of elimination; fecal excretion is less than 2%.
Category C
Category C
Antiviral
Antiviral